Novo Nordisk Lifts Guidance as Wegovy Pill Steals the Show From a Writedown-Hit Bottom Line
Published on 11/04/2026 at 12:10 | Editorial boerse-global.de
Novo Nordisk raised its full-year outlook on Wednesday after third-quarter 2026 results that beat expectations on the adjusted line, with demand for the oral Wegovy pill doing much of the heavy lifting. The headline numbers tell a more complicated story, though: reported profit fell as hefty impairments bit into the bottom line, and the raised guidance still leaves room for contraction.
The Danish drugmaker now expects both adjusted sales and adjusted operating profit to move between ?2% and +2% at constant exchange rates. It marks the third upward revision this year. The new range confirms a better underlying performance but stops short of promising growth — a decline remains within the band, and the forecast assumes international expansion alongside a shrinking US business.
Adjusted strength, reported weakness
Adjusted operating profit for the quarter came in at DKK 31.72bn, up 27% at constant currencies. The reported figure landed at DKK 23.011bn, a currency-adjusted drop of 9%, after Novo booked DKK 8.7bn in impairments tied to a development project and its manufacturing network. Those charges are non-cash but weigh on the audited result, which is why both earnings layers matter: the adjusted metric shows the trajectory without one-offs, while the reported number lays bare the balance-sheet consequences of revaluing pipeline and production capacity.
The oral Wegovy pill generated quarterly revenue of DKK 5.39bn, according to Reuters, comfortably ahead of the DKK 4.62bn analyst consensus and up 53% on the prior quarter. The US picture is more mixed across Wegovy formats. RTÉ reports that US sales of injectable Wegovy fell 13% at constant currencies, while combined US Wegovy revenue rose 21% — a split that argues for judging the franchise as a whole rather than fixating on the syringe.
Momentum is not guaranteed. Management said the pill's prescription curve flattened recently on seasonal factors and is banking on a rebound around Christmas and New Year.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Jefferies stays on the sidelines
Jefferies reiterated its "Hold" rating and DKK 275 price target. Analyst Michael Leuchten noted that adjusted sales beat consensus by 8% and adjusted operating profit by 10%, while pointing to favourable gross-to-net pricing effects as a support behind the outperformance — a reminder that the beat is not purely a demand story.
The stock added 3.2% on the day, a positive reception to the numbers and the higher outlook despite the sizeable earnings charges.
What the guidance revision does and does not prove
Ahead of the release, Jyske Bank had told media it expected Novo to lift the floor of its 2026 guidance, citing the Wegovy pill launches and a stronger-than-forecast Ozempic performance. That was an analyst projection rather than a company decision, and the distinction matters: an anticipated sales decline and a friendlier annual outlook are not mutually exclusive — they describe different lenses on the same business. A raised floor signals a less gloomy read on the current year; it does not by itself certify a durable competitive edge. For that, the operational rationale has to hold up, and product momentum will determine how far the signal carries.
Novo is also pressing on with its share buyback programme, reporting further weekly repurchases on Tuesday. The capital measure is a factor in its own right but no substitute for evidence of operating strength — even in the bullish case, the business trend should carry the argument, not the buyback alone.
Lilly's trial data cast a longer shadow
Competition supplies an independent risk beyond whether the hoped-for guidance hike materialises. Reuters reported on 28 October on Eli Lilly's comments about its investigational drug Retatrutide, which in a diabetes study delivered better blood-sugar control than Ozempic and more than double the weight loss. The findings could raise the bar for Novo's future competitiveness, though the claim has limits: Retatrutide is still experimental, and the study comparison implies neither an accomplished market displacement nor a quantifiable revenue impact. Even so, it stands as a serious counterpoint to the optimistic guidance thesis — a near-term Ozempic improvement would not automatically neutralise longer-run pressure.
Denver and Washington next on the calendar
Scientific engagements follow the print. Novo has flagged twelve abstracts on clinical and care data for semaglutide at the Liver Meeting in Denver from 5 to 9 November, with further contributions scheduled for ObesityWeek in Washington from 14 to 17 November covering CagriSema, care data for the Wegovy pill and STEP Young. Announced presentations are not positive results, but they offer the next opportunities to test the product story alongside the financial guidance.
The 2027 outlook, due in February, will be the first real gauge of what the company expects after a surprisingly strong quarter. Until then, investors will be weighing how long the sales strength and favourable pricing effects can carry — and whether the third upgrade of the year proves a floor or a ceiling.
Ad
Novo Nordisk Stock: New Analysis - 4 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
